BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer

Jae In Park, Jae Hyun Jang, Geun Soo Park, Yunro Chung, Hye Jin You, Jae Hong Kim

Research output: Contribution to journalShort survey

4 Citations (Scopus)

Abstract

Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.

Original languageEnglish (US)
Pages (from-to)373-377
Number of pages5
JournalBMB Reports
Volume51
Issue number8
DOIs
StatePublished - Jan 1 2018

Fingerprint

Leukotriene B4 Receptors
Triple Negative Breast Neoplasms
Biomarkers
Neoplasm Metastasis
Disease-Free Survival
Survival Rate
Breast Neoplasms
Phenotype
Survival
Neoplasms

Keywords

  • BLT2
  • Leukotriene B4 receptor-2
  • TNBC
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer. / Park, Jae In; Jang, Jae Hyun; Park, Geun Soo; Chung, Yunro; You, Hye Jin; Kim, Jae Hong.

In: BMB Reports, Vol. 51, No. 8, 01.01.2018, p. 373-377.

Research output: Contribution to journalShort survey

Park, Jae In ; Jang, Jae Hyun ; Park, Geun Soo ; Chung, Yunro ; You, Hye Jin ; Kim, Jae Hong. / BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer. In: BMB Reports. 2018 ; Vol. 51, No. 8. pp. 373-377.
@article{4d5314498f684d01bdbbad46d6f9b8d9,
title = "BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer",
abstract = "Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.",
keywords = "BLT2, Leukotriene B4 receptor-2, TNBC, Triple-negative breast cancer",
author = "Park, {Jae In} and Jang, {Jae Hyun} and Park, {Geun Soo} and Yunro Chung and You, {Hye Jin} and Kim, {Jae Hong}",
year = "2018",
month = "1",
day = "1",
doi = "10.5483/BMBREP.2018.51.8.127",
language = "English (US)",
volume = "51",
pages = "373--377",
journal = "BMB Reports",
issn = "1976-6696",
publisher = "The Biochemical Society of the Republic of Korea",
number = "8",

}

TY - JOUR

T1 - BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer

AU - Park, Jae In

AU - Jang, Jae Hyun

AU - Park, Geun Soo

AU - Chung, Yunro

AU - You, Hye Jin

AU - Kim, Jae Hong

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.

AB - Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.

KW - BLT2

KW - Leukotriene B4 receptor-2

KW - TNBC

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85055070963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055070963&partnerID=8YFLogxK

U2 - 10.5483/BMBREP.2018.51.8.127

DO - 10.5483/BMBREP.2018.51.8.127

M3 - Short survey

C2 - 29898809

AN - SCOPUS:85055070963

VL - 51

SP - 373

EP - 377

JO - BMB Reports

JF - BMB Reports

SN - 1976-6696

IS - 8

ER -